Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 2,192

Document Document Title
WO/2006/066975A1
Process for the preparation of aryl or vinyl carboxylic acids via Pd-catalysed hydroxycarbonylation of aryl and vinyl bromides, wherein the aryl or vinyl bromides are reacted with a carbon monoxide source comprising lithium formate and a...  
WO/2006/063464A1
A process for preparing betulinic acid (3) comprising subjecting betulin (1) to an electrochemical oxidation reaction to provide a reaction product wherein a primary alcohol function of betulin (1) is converted to an aldehyde functionali...  
WO/2006/064179A1
There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): whe...  
WO/2006/047329A2
A novel monomer composition is described. The novel monomer composition includes at least one property imparting unit. The property imparting unit has at least one member selected from the group consisting of conductivity imparting unit,...  
WO2005118564A3
One aspect of the present invention relates to methods for synthesizing milnacipran or congeners thereof Another aspect of the present invention relates to asymmetric methods for synthesizing enantiomerically enriched milnacipran or cong...  
WO/2006/043519A1
A process which comprises reacting a 1,2,3,4-cyclobutane- tetracarboxylic-1,2:3,4-dianhydride [1] with an alcohol [2] in the presence of an acid catalyst to obtain a compound [3], isomerizing the compound [3] with a base catalyst into a ...  
WO/2006/028776A1
A method for synthesizing compounds of the formula (I) where Cm is a fullerene having m carbon atoms and each R is independently -H or -R” COOH where R is alkyl having 1-20 carbon atoms, substituted alkyl having 1-20 carbon atoms, alke...  
WO/2006/022825A1
Various non-limiting embodiments disclosed herein related to photochromic materials comprising the reaction product of (a) at least one ring-opening cyclic monomer, and (b) a photochromic initiator. Other non-limiting embodiments related...  
WO/2006/009266A1
A selenium compound, a nitrogenous aromatic compound, and an acid are mixed together optionally in the presence of a solvent to obtain an oxidation catalyst composition. The oxidation catalyst composition obtained shows catalytic activit...  
WO/2006/006178A1
This invention relates to novel corosolic acid analogs of the formula I, wherein R1, R2, R3, R4 and R5 are as indicated below in each of said analogs: 1. R1 = COCH3, R2= R3=R4= H, R5= COOH or R1, =R3=R4= H, R2= COCH3,R5= COOH 2. RI= R2= ...  
WO/2006/002470A1
The present invention provides transition metal complexes of enantiomerically enriched compounds for use as catalysts in asymmetric transformations.  
WO/2006/001964A2
The present invention provides moronic acid derivatives of the general Formula (I) which have antiviral activity, along with compositions containing the same and methods of use thereof.  
WO/2005/123649A1
This invention relates to analogs of 3-0-Acetyl-11-Keto-b-Boswellic acid (AKBA) that exhibit 5-Lipoxigenase inhibitory properties. These compounds may be used in pharmaceutical compositions for therapeutic applications against a variety ...  
WO2005009104A3
The present invention is directed to hepatocyte nuclear factor 4a (HNF-4a) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such compounds ...  
WO/2005/123650A1
A novel fluorinated adamantane derivative. It is a compound represented by the formula AF(-COF)n, wherein AF means a fluorinated adamantane residue which is an n-valent group formed by removing n hydrogen atom(s) from adamantane (provide...  
WO/2005/118564A2
One aspect of the present invention relates to methods for synthesizing milnacipran or congeners thereof Another aspect of the present invention relates to asymmetric methods for synthesizing enantiomerically enriched milnacipran or cong...  
WO/2005/110963A1
The present invention relates to compounds having the general formula (I) with the definitions of RI-R3 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds as a medicament, preferab...  
WO2005084141A3
The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of T. nucifera or abietane diterpenoid compound or terpenoid compound isolated from the same as an effectiv...  
WO/2005/095321A1
Accordingly the present invention provides an improved and economical process for the isolation of oleanolic acid from the roots of Lantana camara, resulting in the isolation of oleanolic acid with 1% yield.  
WO/2005/084141A2
The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of T. nucifera or abietane diterpenoid compound or terpenoid compound isolated from the same as an effectiv...  
WO2005049589A3
Disclosed are novel compounds of formula (I), having hypolipidaemic and hypocholesterolemic properties, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acce...  
WO2005047215A3
Processes for the preparation of certain [3.1.0] hexane derivatives which are useful as mGluR agonists, and intermediates prepared during such processes.  
WO/2005/051884A1
[MEANS FOR SOLVING PROBLEMS] A novel cyclic carboxylic acid formed by the addition reaction of an unsaturated carboxylic acid with a conjugated diene compound; a metal salt of the acid; a compounding agent (A) for antifouling coating com...  
WO/2005/049589A2
Disclosed are novel compounds of formula (I), having hypolipidaemic and hypocholesterolemic properties, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acce...  
WO/2005/047215A2
Processes for the preparation of certain [3.1.0] hexane derivatives which are useful as mGluR agonists, and intermediates prepared during such processes.  
WO2004092145A8
Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R...  
WO2004093650A3
The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other s...  
WO/2005/027891A1
An accelerator for initial insulin secretion which contains a triterpene represented by the following general formula (1) and/or a triterpene represented by the following general formula (2).[Chemical formula 1] [In the formulae, R1 is C...  
WO/2005/027892A1
An early insulin secretion promoter comprising corosolic acid and so on. By using this early insulin secretion promoter, insulin can be quickly secreted immediately after eating and, moreover, excessive insulin secretion can be inhibited...  
WO2005009330A3
The invention relates to a method of obtaining inhibitors of the type II dehydroquinase enzyme and the precursors thereof from (-)-quinic acid, the aforementioned compounds having a carboxycyclohexene structure. More specifically, the in...  
WO/2005/019151A1
The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator acti...  
WO/2005/014519A1
The invention relates to a process for the preparation of a substituted geminal difluoroalkane, wherein an oxime is converted to the gerninal difluoroalkane using a nitrite and a complex consisting of HF and an organic base, as well as i...  
WO/2005/009330A2
The invention relates to a method of obtaining inhibitors of the type II dehydroquinase enzyme and the precursors thereof from (-)-quinic acid, the aforementioned compounds having a carboxycyclohexene structure. More specifically, the in...  
WO2004091278A3
The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Me...  
WO/2005/009104A2
The present invention is directed to hepatocyte nuclear factor 4a (HNF-4a) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such compounds ...  
WO/2004/110973A1
The present invention discloses platinum (II) complexes with effective anticancer activity, characterized in that the new platinum (II) complexes are formed by reacting the anionic ligand of Camphoric radicals with the cationic ligand of...  
WO2004076349B1
Disclosed and claimed herein are e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene of the general formula C60R3, wherein each R is independently selected from groups of the formula -CR<1>R<2> wherein each R<1> and R<2> is...  
WO/2004/093650A2
The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other s...  
WO/2004/091278A2
The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Me...  
WO/2004/092145A1
Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R...  
WO2004010512A3
Novel heterodiamondoids are disclosed. These heterodiamondoids are diamondoids that include heteroatoms in the diamond lattice structure. The heteroatoms may be either electron donating, such that an n-type heterodiamondoid is created, o...  
WO/2004/085366A1
Two compounds namely ent-pimmarane 8(14), 15-diene-19 oic acid (compound 1) and ent-pimmarane 7(8), 9(11),15-diene-19 oic acid (compound 2) were isolated from Lavatera cachmeriania, these compounds, in vitro, significantly inhibited the ...  
WO/2004/076349A1
Disclosed and claimed herein are e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene of the general formula C60R3, wherein each R is independently selected from groups of the formula -CR1R2 wherein each R1 and R2 is indepen...  
WO/2004/063169A1
A compound having the following formula (I): wherein R¿1? is N-containing heterocyclic ring optionally substituted with one or more suitable substituent(s), R¿2? is hydroxyamino, R¿3? is hydrogen or a suitable substituent, L¿1? is -(...  
WO/2004/046079A1
The invention relates to optionally isolated and/or purified enantiomers of 2-heptylcyclopropyl-1-carboxylic acid, in addition to mixtures of two, three or all enantiomers of 2-heptylcyclopropyl-1-carboxylic acid, which are used as perfu...  
WO2004031126A3
A process for synthesis of 1-(aminomethyl)cyclohexane acetic acid hydrochloride (Gabapentin hydrochloride) comprising: a) Reaction of a mixture of acetic anhydride/ammonium acetate with 1,1-cyclohexane­diacetic acid to yield 3,3-pentame...  
WO2002079137A9
Novel compounds are disclosed that have specific chemical structures, and prodrug esters and acid-addition salts thereof, that are useful as Interleukin-1 and Tumor Necrosis Factor-a modulators, and thus are useful in the treatment of va...  
WO/2004/037240A1
The present invention relates to the use of compounds of Formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection.  
WO/2004/037241A1
The present invention relates to the use of compounds of formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection.  
WO/2004/031126A2
A process for synthesis of 1-(aminomethyl)cyclohexane acetic acid hydrochloride (Gabapentin hydrochloride) comprising: a) Reaction of a mixture of acetic anhydride/ammonium acetate with 1,1-cyclohexane­diacetic acid to yield 3,3-pentame...  

Matches 151 - 200 out of 2,192